TY - JOUR
T1 - Deep learning can predict cardiovascular events from liver imaging
AU - Veldhuizen, Gregory Patrick
AU - Lenz, Tim
AU - Cifci, Didem
AU - van Treeck, Marko
AU - Clusmann, Jan
AU - Chen, Yazhou
AU - Schneider, Carolin V.
AU - Luedde, Tom
AU - de Leeuw, Peter W.
AU - El-Armouche, Ali
AU - Truhn, Daniel
AU - Kather, Jakob Nikolas
N1 - Funding Information:
JNK is supported by the German Cancer Aid (DECADE, 70115166), the German Federal Ministry of Research, Technology and Space (PEARL, 01KD2104C; CAMINO, 01EO2101; TRANSFORM LIVER, 031L0312A; TANGERINE, 01KT2302 through ERA-NET Transcan; Come2Data, 16DKZ2044A; DEEP-HCC, 031L0315A; DECIPHER-M, 01KD2420A; NextBIG, 01ZU2402A), the German Academic Exchange Service (SECAI, 57616814), the German Federal Joint Committee (TransplantKI, 01VSF21048), the European Union\u2019s Horizon Europe research and innovation programme (ODELIA, 101057091; GENIAL, 101096312), the European Research Council (ERC; NADIR, 101114631), the National Institutes of Health (EPICO, R01 CA263318) and the National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre (grant number NIHR203331). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. This work was funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.
Publisher Copyright:
© 2025 The Authors
PY - 2025
Y1 - 2025
N2 - Background & Aims: Cardiovascular mortality remains the leading cause of death and a significant source of morbidity, with metabolic alterations being key etiological factors. As the main metabolic organ, the liver could predict prodromal changes associated with increased cardiovascular risk. However, quantifying this risk remains challenging. This study explores the use of transformer neural networks on liver magnetic resonance imaging (MRI) data to enhance cardiovascular risk prediction. Methods: Using the extensive collection of liver MRIs in the UK Biobank, we developed a feature extractor with a vision transformer backbone trained in a self-supervised manner. This encoder was then used to predict cardiovascular outcomes from liver MRI scans. Unlike traditional methods, no manual feature selection was required, minimizing bias. Performance was assessed via fivefold cross validation, where predicted risk scores were compared against actual cardiovascular outcomes. Results: The model was trained on 44,672 liver MRIs. In the fivefold cross-validation predicting major adverse cardiac events, the mean AUC was 0.70 with a 95% CI of 0.69–0.72 and p <0.001. The F-statistic from the one-way ANOVA comparing the Systematic Coronary Risk Evaluation 2 (SCORE2) values of the three prediction model score groups was 68.49 with p <0.001. The log-rank test comparing the survival of those with prediction model scores above and below 0.5 had a test statistic of 43 and p <0.001. The multivariate log-rank test comparing the survival of those in the four quartiles of prediction model scores had a test statistic of 61 and p <0.001. Conclusions: Vision transformer-based models demonstrate promise as quantifiable biomarkers for cardiovascular risk assessment by capturing subtle metabolic and vascular information from liver MRI scans. These findings highlight their strong predictive performance and potential value in risk stratification. Further prospective studies and external validation will be required to establish their clinical utility. Impact and implications: Our study demonstrates that deep learning applied to liver MRI can predict cardiovascular risk, highlighting the role of the liver as a metabolic indicator of early cardiovascular disease. These findings are significant for clinicians and researchers seeking non-invasive, imaging-based biomarkers for cardiovascular risk stratification, particularly in patients who might not yet exhibit overt symptoms. If validated in prospective studies, this approach could enhance current risk assessment models, allowing for earlier and more personalized interventions in high-risk individuals. However, further validation is necessary before clinical implementation, ensuring broad applicability and integration into existing prevention frameworks.
AB - Background & Aims: Cardiovascular mortality remains the leading cause of death and a significant source of morbidity, with metabolic alterations being key etiological factors. As the main metabolic organ, the liver could predict prodromal changes associated with increased cardiovascular risk. However, quantifying this risk remains challenging. This study explores the use of transformer neural networks on liver magnetic resonance imaging (MRI) data to enhance cardiovascular risk prediction. Methods: Using the extensive collection of liver MRIs in the UK Biobank, we developed a feature extractor with a vision transformer backbone trained in a self-supervised manner. This encoder was then used to predict cardiovascular outcomes from liver MRI scans. Unlike traditional methods, no manual feature selection was required, minimizing bias. Performance was assessed via fivefold cross validation, where predicted risk scores were compared against actual cardiovascular outcomes. Results: The model was trained on 44,672 liver MRIs. In the fivefold cross-validation predicting major adverse cardiac events, the mean AUC was 0.70 with a 95% CI of 0.69–0.72 and p <0.001. The F-statistic from the one-way ANOVA comparing the Systematic Coronary Risk Evaluation 2 (SCORE2) values of the three prediction model score groups was 68.49 with p <0.001. The log-rank test comparing the survival of those with prediction model scores above and below 0.5 had a test statistic of 43 and p <0.001. The multivariate log-rank test comparing the survival of those in the four quartiles of prediction model scores had a test statistic of 61 and p <0.001. Conclusions: Vision transformer-based models demonstrate promise as quantifiable biomarkers for cardiovascular risk assessment by capturing subtle metabolic and vascular information from liver MRI scans. These findings highlight their strong predictive performance and potential value in risk stratification. Further prospective studies and external validation will be required to establish their clinical utility. Impact and implications: Our study demonstrates that deep learning applied to liver MRI can predict cardiovascular risk, highlighting the role of the liver as a metabolic indicator of early cardiovascular disease. These findings are significant for clinicians and researchers seeking non-invasive, imaging-based biomarkers for cardiovascular risk stratification, particularly in patients who might not yet exhibit overt symptoms. If validated in prospective studies, this approach could enhance current risk assessment models, allowing for earlier and more personalized interventions in high-risk individuals. However, further validation is necessary before clinical implementation, ensuring broad applicability and integration into existing prevention frameworks.
KW - Biomarker development
KW - Cardiovascular risk
KW - Deep learning
KW - Liver MRI
KW - Major adverse cardiac events (MACE)
KW - Risk stratification
KW - Self-supervised learning (SSL)
KW - Survival analysis
KW - UK Biobank
KW - Vision transformer (ViT)
U2 - 10.1016/j.jhepr.2025.101427
DO - 10.1016/j.jhepr.2025.101427
M3 - Article
SN - 2589-5559
VL - 7
JO - JHEP Reports
JF - JHEP Reports
IS - 8
M1 - 101427
ER -